



April 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-003348-63/ Novartis Protocol ID CBPS804A2204

A randomized, placebo-controlled trial of BPS804 on safety and tolerability in patients with late-stage chronic kidney disease

Trial CBPS804A2204 was cancelled with no patient enrollment and as such, no results will be reported.